Shares in Insulet (NSDQ:PODD) rose today after the company met earnings expectations on Wall Street and beat sales estimates with its second quarter results.
The Billerica, Mass.-based company posted a net loss of -$7.8 million, or -13¢ per share, on sales of $109.8 million for the 3 months ended June 30, for bottom-line loss of -85% on sales growth of 26% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulet Q2 sales tops estimates appeared first on MassDevice.
from MassDevice http://ift.tt/2huPuTg
Cap comentari:
Publica un comentari a l'entrada